Header image  
   
  
 


 
 
 
Clinic:

1399 S. Roxbury Drive
Suite 100
Los Angeles, CA 90035
310-557-2273
Research line: 310-557-9680

Administration:

9911 W. Pico Blvd.
Suite 980
Los Angeles, CA 90035
310-557-1891


 
 
Phase II research study of combined modality therapy plus cetuximab in HIV associated anal cancer (AMC 045)

This study is designed to determine whether the addition of cetuximab to standard chemotherapy and radiation reduces the failure rate of this therapy. All participants will be given combined modality therapy (chemotherapy and radiation) plus cetuximab. Participants will be followed for up to 5 years.

Inclusion Criteria:

  • Men and women 18 years or older
  • Documented HIV infection
  • Biopsy proven stage I to IIIB invasive anal canal or perianal squamous cell cancer.

Exclusion criteria:

  • Current active serious opportunistic infection
  • A CD4 cell count below 50 mL if in conjunction with an opportunistic infection within the past 6 months
  • Prior invasive cancer within the last two years
  • Grade 2, 3 or 4 neuropathy
  • Severe or poorly controlled diarrhea
  • Pregnancy or breast feeding

This study is being conducted by Dr. Ronald Mitsuyasu under IRB #06-05-094-01

If you think you might be interested in participating in this study, please contact Deon Claiborne at 310-557-9062 or email at dclaiborne@mednet.ucla.edu

Return to Clinical Trials main page

 


 

 

   
 
     
     
     
     
     
UCLA Center for Clinical
AIDS Research & Education
UCLA Health Sciences
UCLA Campus
Terms and Conditions
Privacy Practices
UCLA AIDS Institute